Literature DB >> 8889675

Detection of methamphetamine in sweat by EIA and GC-MS.

J Fay1, R Fogerson, D Schoendorfer, R S Niedbala, V Spiehler.   

Abstract

Sweat was collected with the PharmChekTM sweat patch and drugs were eluted from the collection pad of the patch. A solid phase, enzyme immunoassay using microtiter plates was modified for analysis of methamphetamine in sweat. After methamphetamine administration, sweat contains primarily parent methamphetamine. The immunoassay was determined to have crossreactivity relative to 100% for the methamphetamine (MA) calibrators; to 144% for methylenedioxymethamphetamine (MDMA); to 30% for d-amphetamine; to 21% for methylenedioxyamphetamine (MDA); and to 8% for I-methamphetamine. The optimum cutoff concentration for this modified assay was determined by receiver operating characteristic analysis to be 10 ng/mL amphetamine equivalents. At this cutoff concentration the assay had a diagnostic sensitivity of 84.5% and a diagnostic specificity of 93.2% versus gas chromatography-mass spectrometry (GC-MS). The positive predictive value at a prevalence of 50% was 86%. The intra-assay precision at 10 ng/mL was 9.9% (coefficient of variation, CV) and the interassay CV was 13%. Analysis of spiked patches at plus or minus 25 and 50% around the cutoff gave a percent positive threshold of approximately 50% at a cutoff of 10 ng/mL and a 95% confidence level for a positive result by the EIA between 15 and 20 ng/mL. Of 18 potential adulterants that might be injected into or under the patch, two (tile cleaner and cough syrup) caused a false-positive response by immunoassay. All results were confirmed by GC-MS. The clinical sensitivity and specificity of the overall analysis system (sweat collection and analysis) were 85 and 100%, respectively, using known methamphetamine dosing of volunteers (10, 20, and 25 mg) as the reference standard.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8889675     DOI: 10.1093/jat/20.6.398

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  5 in total

Review 1.  Bioanalytical procedures for monitoring in utero drug exposure.

Authors:  Teresa Gray; Marilyn Huestis
Journal:  Anal Bioanal Chem       Date:  2007-03-17       Impact factor: 4.142

2.  Excretion of methamphetamine and amphetamine in human sweat following controlled oral methamphetamine administration.

Authors:  Allan J Barnes; Michael L Smith; Sherri L Kacinko; Eugene W Schwilke; Edward J Cone; Eric T Moolchan; Marilyn A Huestis
Journal:  Clin Chem       Date:  2007-11-02       Impact factor: 8.327

3.  Excretion of Delta9-tetrahydrocannabinol in sweat.

Authors:  Marilyn A Huestis; Karl B Scheidweiler; Takeshi Saito; Neil Fortner; Tsadik Abraham; Richard A Gustafson; Michael L Smith
Journal:  Forensic Sci Int       Date:  2007-05-03       Impact factor: 2.395

Review 4.  Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices.

Authors:  Rafael de la Torre; Magí Farré; Mónica Navarro; Roberta Pacifici; Piergiorgio Zuccaro; Simona Pichini
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

5.  Development and validation of a disk solid phase extraction and gas chromatography-mass spectrometry method for MDMA, MDA, HMMA, HMA, MDEA, methamphetamine and amphetamine in sweat.

Authors:  Bruno S De Martinis; Allan J Barnes; Karl B Scheidweiler; Marilyn A Huestis
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-02-15       Impact factor: 3.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.